KOCAA
RVNC

Knights of Columbus Asset Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-50,002
Closed -$1.22M – 340
2020
Q2 		$1.22M Sell
50,002
-15,777
-24% -$311K 0.15% 220
2020
Q1 		$974K Sell
65,779
-41,184
-39% -$852K 0.12% 247
2019
Q4 		$1.74M Buy
+106,963
New +$1.66M 0.15% 238

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Knights of Columbus Asset Advisors's RVNC Position: Q3 2020 in Review

Knights of Columbus Asset Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2020, closing a stake of 50,002 shares — an estimated $1.22M sold.

Knights of Columbus Asset Advisors first reported a position in RVNC in Q4 2019 and held it in 3 quarters. The position peaked at $1.74M in Q4 2019. 153 funds tracked by Wall St. Rank hold RVNC as of Q3 2020.

  • Knights of Columbus Asset Advisors reported no remaining Revance Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Knights of Columbus Asset Advisors sold 50,002 Revance Therapeutics, Inc. shares in Q3 2020, an estimated $1.22M.
  • Knights of Columbus Asset Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2019 and held it in 3 quarters.
  • Knights of Columbus Asset Advisors's Revance Therapeutics, Inc. position peaked at $1.74M in Q4 2019.
  • 153 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2020.

Based on Knights of Columbus Asset Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.